WO2012170431A3 - Systèmes perfectionnés de commutation génique - Google Patents

Systèmes perfectionnés de commutation génique Download PDF

Info

Publication number
WO2012170431A3
WO2012170431A3 PCT/US2012/040932 US2012040932W WO2012170431A3 WO 2012170431 A3 WO2012170431 A3 WO 2012170431A3 US 2012040932 W US2012040932 W US 2012040932W WO 2012170431 A3 WO2012170431 A3 WO 2012170431A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved
systems
present
provides
geneswitch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/040932
Other languages
English (en)
Other versions
WO2012170431A2 (fr
Inventor
Robert H. KUTNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of WO2012170431A2 publication Critical patent/WO2012170431A2/fr
Publication of WO2012170431A3 publication Critical patent/WO2012170431A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C12N2740/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des systèmes perfectionnés d'expression génique à commutation moléculaire et une production perfectionnée de cellules d'encapsidation de rétrovirus et de particules virales. Dans divers modes de réalisation, la présente invention concerne également des vecteurs rétroviraux qui ont un contrôle accru vis-à-vis de l'expression génique. La présente invention concerne en outre des systèmes de vecteurs qui sont utiles dans des méthodes de thérapie génique.
PCT/US2012/040932 2011-06-06 2012-06-05 Systèmes perfectionnés de commutation génique Ceased WO2012170431A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493918P 2011-06-06 2011-06-06
US61/493,918 2011-06-06

Publications (2)

Publication Number Publication Date
WO2012170431A2 WO2012170431A2 (fr) 2012-12-13
WO2012170431A3 true WO2012170431A3 (fr) 2013-04-25

Family

ID=47296699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/040932 Ceased WO2012170431A2 (fr) 2011-06-06 2012-06-05 Systèmes perfectionnés de commutation génique

Country Status (1)

Country Link
WO (1) WO2012170431A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108359014A (zh) * 2018-02-08 2018-08-03 四川农业大学 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法
CN109402178B (zh) * 2018-11-16 2021-08-03 佛山科学技术学院 一种小鼠精原干细胞高效重编程的方法及应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201318954D0 (en) 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
ES2578903B1 (es) * 2015-01-02 2017-07-07 Instituto De Salud Carlos Iii Vector lentiviral de expresión autolimitada
WO2016118715A1 (fr) * 2015-01-21 2016-07-28 Cornell University Vecteurs viraux pour la prophylaxie et la thérapie d'hémoglobinopathies
DE102016122317A1 (de) 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Transientes transfektionsverfahren für retrovirale produktion
US20170145388A1 (en) * 2015-11-24 2017-05-25 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
GB201603374D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
WO2017223330A1 (fr) 2016-06-22 2017-12-28 Icahn School Of Medicine At Mount Sinai Administration virale d'arn à l'aide de ribozymes à auto-clivage et applications basées sur crispr
EP3548005A4 (fr) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes destinés à l'administration d'agents thérapeutiques
AU2019325609A1 (en) 2018-08-24 2021-03-18 Csl Behring Gene Therapy, Inc. Vector production in serum free media
WO2021041787A1 (fr) * 2019-08-29 2021-03-04 G Tech Bio Llc Compositions et méthodes pour le traitement d'infections virales
EP4117725A4 (fr) 2020-03-09 2024-05-29 Arcturus Therapeutics, Inc. Méthodes et compositions de vaccin contre le coronavirus
CN112143754B (zh) * 2020-09-30 2021-05-18 扬州大学 猪盖塔病毒感染性克隆及其建构方法及应用
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN113322282A (zh) * 2021-04-20 2021-08-31 华南农业大学 稳定表达NS1蛋白的犬肾细胞系MDCK-pCDH-NS1及其构建方法和应用
CN117304276B (zh) * 2023-11-30 2024-04-12 江门海关技术中心 含口蹄疫病毒o型和塞内卡病毒核酸的病毒样颗粒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014836A2 (fr) * 2003-08-08 2005-02-17 Cambridge University Technical Services Limited Systeme de vecteurs chimeriques
WO2005026316A2 (fr) * 2003-09-15 2005-03-24 Bioption Ab Vaccins contre les arbovirus
US20080241929A1 (en) * 1999-04-29 2008-10-02 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20100221789A1 (en) * 2002-02-01 2010-09-02 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241929A1 (en) * 1999-04-29 2008-10-02 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20100221789A1 (en) * 2002-02-01 2010-09-02 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2005014836A2 (fr) * 2003-08-08 2005-02-17 Cambridge University Technical Services Limited Systeme de vecteurs chimeriques
WO2005026316A2 (fr) * 2003-09-15 2005-03-24 Bioption Ab Vaccins contre les arbovirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SURYANARAYANA, V. V. S. ET AL.: "Non-segmented negative sense RNA viruses as vectors for vaccine development", CURRENT SCIENCE, vol. 98, no. 3, 10 February 2010 (2010-02-10), pages 379 - 391, XP055066072 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108359014A (zh) * 2018-02-08 2018-08-03 四川农业大学 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法
CN109402178B (zh) * 2018-11-16 2021-08-03 佛山科学技术学院 一种小鼠精原干细胞高效重编程的方法及应用

Also Published As

Publication number Publication date
WO2012170431A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012170431A3 (fr) Systèmes perfectionnés de commutation génique
WO2013014294A3 (fr) Systèmes d'expression de baculovirus perfectionnés
WO2014093661A3 (fr) Systèmes crispr-cas et procédés pour modifier l'expression de produits de gène
WO2014077866A8 (fr) Vecteurs réplicatifs en minicercle avec une expression améliorée
MX347453B (es) Canalrodopsina 2 mutante.
EP4089172A3 (fr) Système de vecteur multiple et ses utilisations
EP4273257A3 (fr) Système de coexpression inductible
HK1207665A1 (en) Polypeptides having transgalactosylating activity
WO2013102144A8 (fr) Variants du polypeptide ph20, formulations en contenant et leurs utilisations
WO2012094560A3 (fr) Promoteurs, cassettes d'expression, vecteurs, kits, et procédés pour le traitement de l'achromatopsie et d'autres maladies
HK1211981A1 (en) Methods to control protein heterogeneity
WO2013063383A3 (fr) Vecteurs codant pour un facteur de viabilité des cônes dérivé des bâtonnets
WO2012162534A3 (fr) Peptidoglycanes synthétiques se liant à l'acide hyaluronique, préparation et procédés d'utilisation
WO2012156839A9 (fr) Nouvelle génération de vecteurs lentiviraux sans épissures pour des applications de thérapie génique plus sûres
EP3246406A4 (fr) Système d'expression génique mettant en oeuvre un arn furtif, et vecteur d'introduction/expression de gène comprenant ledit arn
HK1213521A1 (zh) Fix多肽的應用
EP3760713A3 (fr) Variants lipasiques et polynucléotides codant pour ceux-ci
WO2011084647A3 (fr) Système d'immunité vis-à-vis des toxines
WO2012087327A3 (fr) Systèmes de polymères
MY181566A (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2014097318A3 (fr) Agents pour éliminer des cellules d'initiation tumorale
WO2013053857A3 (fr) Grappe de gènes pour la biosynthèse de la grisélimycine et de la méthylgrisélimycine
WO2014036524A3 (fr) Cellules souches mésenchymateuses (msc) génétiquement modifiées et méthodes thérapeutiques
HK1206201A1 (en) Modified erythrocyte precursor cells and uses thereof
WO2012010976A3 (fr) Variants de méganucléases clivant une séquence d'adn cible dans le gène tert et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796118

Country of ref document: EP

Kind code of ref document: A2